4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester,
4-(4-(5-nitrofuran-2-ylmethylene)-3, 5-dioxopyrazolidin-1-yl)benzoic acid ethyl ester,
PYR-41,
PYR41 compound,
PYR-41,
418805-02-4,
PYR 41,
PYR41,
C17H13N3O7,
ethyl 4-[(4Z)-4-[(5-nitrofuran-2-yl)methylidene]-3,5-dioxopyrazolidin-1-yl]benzoate,
AKOS002343406,
AC1NSKPD,
SCHEMBL8244763,
CHEMBL2322201,
AKL-PFC-523155,
AOB3015,
DTXSID30416554,
BCP10065,
Benzoic acid, 4-[4-[(5-nitro-2-furanyl)methylene]-3,5-dioxo-1-pyrazolidinyl]-, ethyl ester,
EX-A2145,
ZINC5009986,
BN0841,
MFCD01469983,
NSC746131,
s7129,
AKOS000542559,
ACN-028911,
CS-1724,
NSC-746131,
BC600473,
HY-13296,
SW220249-1,
Y1866,
SR-01000215370,
SR-01000215370-1,
4-(4-(5-Nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester,
4[4-(5-Nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester,
pyrazone-41,
PYR41 compound,
Ubiquitin E1 Inhibitor, PYR-41,
CID5335621,
A13254,
C523934,
4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester,
4-(4-(5-nitrofuran-2-ylmethylene)-3, 5-dioxopyrazolidin-1-yl)benzoic acid ethyl ester,
Ethyl 4-[4-[(5-nitro-2-furyl)methylidene]-3,5-dioxo-pyrazolidin-1-yl]benzoate,